Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Biofidelity launches Aspyre Clinical Test for Lung

December 2024—Biofidelity announced the launch of its Aspyre Clinical Test for Lung for liquid biopsy samples. Using either a tissue or blood sample, the test detects somatic mutations from DNA and gene fusions from RNA within two days. “Currently, patients who are fortunate enough to receive molecular testing often have to wait weeks for the results, with many tests failing altogether,” Barnaby Balmforth, PhD, Biofidelity cofounder and CEO, said in a press statement. “Aspyre Clinical Test for Lung’s unmatched next-day turnaround time coupled with its best-in-class performance from tissue and blood and proven performance with challenging samples makes simplified genomic profiling via Aspyre a game-changer for patients and the clinicians treating them.”

Qiagen calls for increased TB testing in U.S. for at-risk people

December 2024—Qiagen has called for a sharper focus on testing strategies to stop new cases of tuberculosis from erupting and spreading in the United States. The U.S. has maintained one of the lowest TB rates in the world, but case counts across all age groups have risen every year since 2020, including a 16 percent increase in cases from 8,320 in 2022 to 9,615 in 2023 (Williams PM, et al. MMWR Morb Mortal Wkly Rep. 2024;73[12]:265–270). The American Academy of Pediatrics updated its TB screening guidelines this year to encourage use of blood-based testing for children of all ages, including from birth to two years old.

FoundationOne Liquid CDx OK’d for Tepmetko

December 2024—Foundation Medicine announced it has received approval from the FDA for FoundationOne Liquid CDx to be used as a companion diagnostic for tepotinib (Tepmetko, EMD Serono). Tepmetko received accelerated approval from the FDA in February 2021 and traditional approval in February 2024 for the treatment of adult patients with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition exon 14 skipping alterations.

Illumina expands TruSight Oncology portfolio

December 2024—Illumina announced it will release TruSight Oncology 500 v2, a new version of its flagship cancer research assay to enable comprehensive genomic profiling. The assay is under development; a worldwide release is planned for midyear 2025. TSO 500 v2 assesses hundreds of genes across all variant classes, as well as immuno-oncology biomarkers, in a single assay from one sample. Features of the new version include a faster turnaround time and reduced hands-on time; sensitive variant calling and improved coverage of difficult genomic regions; and new kit configurations with 50 percent less packaging, 70 percent fewer tubes, and improved usability.

Verichem offers reference materials for cholesterol assays

December 2024—Verichem Laboratories announced that it is now offering clinical reference materials intended for calibration and calibration verification procedures for total cholesterol, high-density lipoprotein, and low-density lipoprotein. The liquid-stable, ready-to-use Matrix Plus Total Cholesterol Reference kit, Matrix Plus Total Cholesterol Reference kit level F, and HDL Cholesterol Verifier kit feature universal compatibility with a variety of automated clinical chemistry systems. The serum-like formulation contains a blend of highly purified human source material and bovine biologicals in saline.

Revvity’s Euroimmun launches APOE PCR test

December 2025—Revvity has launched its in vitro diagnostic EuroRealTime APOE assay in European countries that accept the CE mark. The test aims to help assess a patient’s risk for side effects prior to the start of an anti-amyloid therapy for Alz­heimer’s disease. The real-time APOE PCR test allows simultaneous detection of the three most frequent APOE forms—E2, E3, and E4. Assay processing can be automated to scalable degrees on Revvity instruments, including the Euroimmun PreNAT II and Chemagic 360 platforms. Results are evaluated, documented, and archived using EuroRealTime analysis software.

FDA approves Roche CDx for biliary tract cancer

December 2024—Roche announced FDA approval of a label expansion into biliary tract cancer for the Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, a companion diagnostic to aid in the assessment of HER2-positive status to identify patients with biliary tract cancer who are eligible for treatment with zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals). Ziihera is an FDA-approved treatment for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. The Pathway HER2 (4B5) test is used in combination with the Ventana BenchMark slide staining instrument.

FDA OKs Kisqali in people with HR+/HER2- early breast cancer

November 2024—Novartis announced FDA approval of Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of people with HR+/HER2- stage II and III early breast cancer at high risk of recurrence, including those with node-negative disease.

Qiagen expands agreement with AstraZeneca

November 2024—Qiagen has expanded its master collaboration agreement with AstraZeneca to develop and commercialize companion diagnostics for therapies being developed by AstraZeneca to address chronic diseases.

MARKETPLACE

TRENDING